T. Rowe Price Associates’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-38,723
| Closed | -$163K | – | 3034 |
|
|
2023
Q1 | $163K | Buy |
38,723
+1,130
| +3% | +$4.76K | ﹤0.01% | 2577 |
|
|
2022
Q4 | $226K | Buy |
37,593
+1,654
| +5% | +$9.94K | ﹤0.01% | 2486 |
|
|
2022
Q3 | $210K | Buy |
35,939
+6,900
| +24% | +$40.3K | ﹤0.01% | 2521 |
|
|
2022
Q2 | $173K | Buy |
29,039
+1,639
| +6% | +$9.76K | ﹤0.01% | 2628 |
|
|
2022
Q1 | $128K | Sell |
27,400
-5,300
| -16% | -$24.8K | ﹤0.01% | 2798 |
|
|
2021
Q4 | $81K | Hold |
32,700
| – | – | ﹤0.01% | 2894 |
|
|
2021
Q3 | $96K | Hold |
32,700
| – | – | ﹤0.01% | 2849 |
|
|
2021
Q2 | $82K | Hold |
32,700
| – | – | ﹤0.01% | 2860 |
|
|
2021
Q1 | $95K | Buy |
+32,700
| New | +$95K | ﹤0.01% | 2780 |
|
|
2015
Q1 | – | Sell |
-396,000
| Closed | -$9.35M | – | 2624 |
|
|
2014
Q4 | $9.35M | Buy |
+396,000
| New | +$9.35M | ﹤0.01% | 1343 |
|